Abeona reports $71.2M net income in FY 2025; first ZEVASKYN patient treated

ABEONA THERAPEUTICS INC.

First ZEVASKYN commercial patient treated in Dec 2025; net product revenue $2.4M; one patient treated in Q1 2026 with more biopsies collected.
Total revenue $5.8M including $3.4M license revenue from Taysha milestone; PRV sale net gain $152.4M.
Net income $71.2M ($1.34 basic EPS) vs loss of $63.7M in 2024; cash $191.4M as of Dec 31, 2025.
R&D spend decreased to $26.8M; SG&A increased to $65.0M due to commercial transition post-FDA approval.
Expanding patient access: fourth QTC activated at UTMB Galveston; building launch momentum.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ABEONA THERAPEUTICS INC. reported year ended December 31, 2025 results: revenue $5.8 million, net income $71.2 million, EPS $1.34 per basic and $1.01 per diluted common share.

Period: year ended December 31, 2025
Revenue: $5.8 million
Net income: $71.2 million
EPS: $1.34 per basic and $1.01 per diluted common share
Result: reported results

Exact text from the filing

Abeona reported total revenue of $5.8 million for the year ended December 31, 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ABEONA THERAPEUTICS INC. reported year ended December 31, 2025 results: revenue $5.8 million, net income $71.2 million, EPS $1.34 per basic and $1.01 per diluted common share.

Period: year ended December 31, 2025
Revenue: $5.8 million
Net income: $71.2 million
EPS: $1.34 per basic and $1.01 per diluted common share
Result: reported results

Exact text from the filing

major academic medical center renowned for its expertise in comprehensive complex skin disease and wound care. Full Year 2025 Financial Results Abeona reported total revenue of $5.8 million for the year ended December 31, 2025. This was comprised of $3.4 million in license and other revenues and $2.4 million in net product revenue. License and other revenues were

View on SEC.gov

52 earnings releases filed in the last 30 days. Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-010408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.